Nov 6 (Reuters) - Novavax NVAX.O beat Wall Street expectations for third-quarter revenue on Thursday, helped by milestone payments tied to its COVID-19 vaccine partnerships.
The biotech firm reported total revenue of $70.4 million, compared with analysts' average estimate of $42.13 million, according to data compiled by LSEG.
(Reporting by Siddhi Mahatole in Bengaluru)
((siddhi.mahatole@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.